ResearcherGerman Cancer Research CenterActive in the last 2 years

Doaa M. Ali

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5110707037. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. Co-author DOI 10.1016/j.peptides.2023.171111 ↗
Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreatic cancer cells. Co-author DOI 10.1038/s41420-019-0206-2 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Martin Reinhold Berger · 2 shared papers, 2019–2024 · strength 0.32
- Paper EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. DOI 10.1016/j.peptides.2023.171111 ↗
- Paper Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreat… DOI 10.1038/s41420-019-0206-2 ↗
Diana Behrens · 1 shared paper, 2024 · strength 0.20
- Paper EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. DOI 10.1016/j.peptides.2023.171111 ↗
Wolf‐Georg Forssmann · 1 shared paper, 2024 · strength 0.20
- Paper EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. DOI 10.1016/j.peptides.2023.171111 ↗
Micah N. Sagini · 1 shared paper, 2024 · strength 0.20
- Paper EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. DOI 10.1016/j.peptides.2023.171111 ↗
Ergül Eyol · 1 shared paper, 2024 · strength 0.20
- Paper EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. DOI 10.1016/j.peptides.2023.171111 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.